These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1124 related articles for article (PubMed ID: 3912244)

  • 1. Vitiligo-related pigment cell differentiation antigens are expressed on malignant melanoma cells following phenotypic reversion induced by contact inhibitory factor.
    Lipkin G; Naughton GK; Rosenberg M; Bystryn JC
    Differentiation; 1985; 30(1):35-9. PubMed ID: 3912244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of vitiligo antigen on a revertant line of hamster melanoma cells.
    Naughton GK; Lipkin G; Bystryn JC
    J Invest Dermatol; 1984 Nov; 83(5):317-9. PubMed ID: 6386993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contact inhibitory factor also restores anchorage and serum dependence to hamster melanoma cells.
    Lipkin G; Rosenberg M; Klaus-Kovtun V
    J Invest Dermatol; 1986 Sep; 87(3):305-8. PubMed ID: 3734481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.
    Cui J; Bystryn JC
    Arch Dermatol; 1995 Mar; 131(3):314-8. PubMed ID: 7887661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies to surface antigens of pigmented cells in animals with vitiligo.
    Naughton GK; Mahaffey M; Bystryn JC
    Proc Soc Exp Biol Med; 1986 Mar; 181(3):423-6. PubMed ID: 3511476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of antibodies to human melanoma cell in vitiligo by western blot analysis.
    Hann SK; Kim JB
    Yonsei Med J; 1995 Nov; 36(5):457-61. PubMed ID: 8546004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?
    Ram M; Shoenfeld Y
    Ann N Y Acad Sci; 2007 Sep; 1110():410-25. PubMed ID: 17911456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.
    Kiniwa Y; Fujita T; Akada M; Ito K; Shofuda T; Suzuki Y; Yamamoto A; Saida T; Kawakami Y
    Cancer Res; 2001 Nov; 61(21):7900-7. PubMed ID: 11691810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of autoantibody to melanocytes and characterization of vitiligo antigen in vitiligo patients.
    Park YK; Kim NS; Hann SK; Im S
    J Dermatol Sci; 1996 Feb; 11(2):111-20. PubMed ID: 8869031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Restoration of growth contact inhibition in malignant melanocytes from man, mice, and hamsters].
    Lipkin G; Knecht ME
    Schweiz Med Wochenschr; 1975 Oct; 105(42):1360-4. PubMed ID: 1226513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposome-entrapped contact inhibitory factor: transfer of capacity for density-dependent growth to melanoma cells.
    Fass E; Lipkin G; Rosenberg M
    J Invest Dermatol; 1986 Sep; 87(3):309-12. PubMed ID: 3734482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pigment transformation and induction in hamster malignant amelanotic melanocytes. An effect of nucleic acids from hamster benign blue nevus.
    Lipkin G
    J Invest Dermatol; 1971 Jul; 57(1):49-65. PubMed ID: 5556532
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of pigment cell antigens defined by vitiligo antibodies.
    Cui J; Harning R; Henn M; Bystryn JC
    J Invest Dermatol; 1992 Feb; 98(2):162-5. PubMed ID: 1370675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Western blot analysis of serum antibody reactivity with human melanoma cell antigens in alopecia areata and vitiligo.
    Galbraith GM; Miller D; Emerson DL
    Clin Immunol Immunopathol; 1988 Sep; 48(3):317-24. PubMed ID: 3042212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanosomal antigenic expression on the cell surface and intracellular subunits within melanogenic compartments of pigment cells: analysis by antimelanosome-associated monoclonal antibody.
    Hayashibe K; Mishima Y; Ichihashi M; Kawai M
    J Invest Dermatol; 1986 Jul; 87(1):89-94. PubMed ID: 3522755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A diffusible factor restoring contact inhibition of growth to malignant melanocytes.
    Lipkin G; Knecht ME
    Proc Natl Acad Sci U S A; 1974 Mar; 71(3):849-53. PubMed ID: 4522794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility to NK cell lysis is abolished in tumor cells by a factor which restores their contact inhibited growth.
    Nabi ZF; Zucker-Franklin D; Lipkin G; Rosenberg M
    Cancer; 1986 Oct; 58(7):1461-5. PubMed ID: 2427188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
    Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
    Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitiligo autoantibodies are effective against melanoma.
    Fishman P; Azizi E; Shoenfeld Y; Sredni B; Yecheskel G; Ferrone S; Zigelman R; Chaitchik S; Floro S; Djaldetti M
    Cancer; 1993 Oct; 72(8):2365-9. PubMed ID: 8402450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to normal human melanocytes in vitiligo.
    Naughton GK; Eisinger M; Bystryn JC
    J Exp Med; 1983 Jul; 158(1):246-51. PubMed ID: 6345714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.